ArticleMolecular diversity2026
Design, synthesis, antibacterial activity evaluation, and mechanism of action study of novel pyrrolidine derivatives containing sulfonamide structures.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Bacterial biofilms serve as innate protective frameworks, sheltering embedded microbes to sustain their survival while potentially enhancing antimicrobial resistance by blocking bactericide penetration. While extensive research has focused on planktonic bacteria, biofilm recalcitrance remains understudied, leaving conventional antimicrobials often ineffective against these sessile communities. This underscores an urgent need for next-generation agents with specialized biofilm-inhibiting properties to enabling effective antibacterial therapy; in this study, we used pyrrolidine-3-carboxylic acid as a starting material to synthesize a series of sulfonamide-containing pyrrolidine derivatives via an active coupling reaction. Compound A14 exhibited the strongest activity, with an EC₅₀ value of 38.33 μg/mL against Xanthomonas oryzae pv. oryzae (Xoo). Mechanistic investigations revealed that A14 suppresses extracellular polymeric substance (EPS) biosynthesis and bacterial motility-key drivers of pathogenicity, biofilm development, and plant cell wall degradation. Conductivity measurements and protein leakage assays confirmed that A14 disrupts multiple Xoo physiological functions, positioning it as a promising antimicrobial candidate targeting core mechanisms of bacterial plant diseases.
Indexed as
Identifiers
42295689What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.